The first human patient was vaccinated with a breakthrough virus that kills cancer, after successful animal testing, with a reduction in colon, lung, ovarian and pancreatic tumors.
The virus, known as Vaxinia, has been genetically engineered to infect, replicate and kill cancer cells. And it spares healthy cells!
The virus was developed by Limited immunogenican Australian company specializing in new therapies that activate the immune system against cancer.
“Our previous research has demonstrated that oncolytic viruses can stimulate the immune system to respond and kill cancer, as well as stimulate the immune system to be more responsive to other immunotherapies, including checkpoint inhibitors” , said Daneng Li MD, head of research and assistant professor. from the Department of Medical Oncology and Therapeutic Research of Cidade da Esperança.
Vaxinia, or CF33-hNIS VAXINIA, is a type of ‘oncolytic virus’ – a naturally occurring virus that has been genetically modified specifically to fight cancer.
Animal tests have shown Vaxinia to be able to reduce the size of cancerous tumors of the colon, lung, breast, ovary and pancreas.
And the best thing is that, unlike other treatments, Vaxinia was able to boost the patient’s immune system and increase the level of a protein called PD-L1 in tumors, making immunotherapy more effective against cancer.
“Now is the time to further increase the power of immunotherapy, and we believe that CF33-hNIS has the potential to improve outcomes for our patients in their fight against cancer.”
The Phase 1 clinical trial aims to enroll 100 cancer patients with metastatic or advanced solid tumors at approximately 10 sites in the United States and Australia.
This stage should last about 24 months, or 2 years.
Patients will start by receiving a low dose of Vaxinia, either by injection directly into the tumors or intravenously.
Once Vaxine is proven safe, some participants will also receive an immunotherapy drug called pembrolizumab, which improves the immune system’s ability to fight cancer cells.
“Interestingly, the same characteristics that eventually make cancer cells resistant to chemotherapy or radiation therapy actually increase the success of oncolytic viruses such as CF33-hNIS,” said Yuman Fong, director of oncology. surgery at City of Hope and main developer of the genetically modified virus.
The clinical trial used live coxsackievirus, one of many viruses that can cause the common cold, in combination with pembrolizumab.
Researchers say the combination shrank melanoma tumors in nearly half (47%) of 36 men and women who received the treatment over a few weeks for at least two years.
Watch the interview with the scientists:
With information from daily mail